BriaCell Therapeutics (BCTX) announced updated Phase 2 survival data for its immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor. The company said data showed a meaningful survival advantage in heavily pretreated metastatic breast cancer patient subtypes. In Triple negative breast cancer: median overall survival was 13.9 months vs. 11.8 months for antibody drug conjugate Trodelvy and 6.9 months single agent chemotherapy data. In Hormone receptor positive: median overall survival was 17.3 months vs. 14.4 months for Trodelvy and 11.2 months in single agent chemotherapy data.
William V. Williams, BriaCells CEO, said: "BriaCell's patients had failed a median of six prior therapies, underscoring the potential clinical impact of our immunotherapy. We look forward to validating these findings in our ongoing pivotal Phase 3 study with overall survival as its primary endpoint."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.